[ET Net News Agency, 13 April 2022] HSBC Global Research lowered its target price for
Sino Biopharm (01177) to HK$8.5 from HK$9 and maintained its "buy" rating.
The research house said it slightly revises down 2022e and 2023e product sales by 2-3%
to RMB31.0 and RMB35.7bn, to factor in slower sales growth in generics like Suchang. (RC)